Bing G Wang

US Patent:

62917056, Sep 18, 2001

Filed:

Mar 24, 2000

Appl. No.:

9/535283

Inventors:

W. S. Winston Ho - Lexington KY
Bing Wang - Richmond VA

Assignee:

Commodore Separation Technologies, Inc. - New York NY

International Classification:

C07F 906

US Classification:

562 9

Abstract:

The present invention provides a novel class of extractants and a method of manufacture for the extractants. The extractants are useful for the removal and recovery of metals from waste waters and process streams. The removal process utilizes a combination of a supported liquid membrane (SLM) and a strip dispersion to improve extraction of the target species while increasing membrane stability and reducing processing costs. The new class of extractants include dialkyl phosphoric acids containing alkyl chains of at least 8-12 carbon atoms. The method of manufacture includes mixing phosphorus pentasulfide with an alcohol, followed by hydrolysis of the intermediate reactants with a mineral acid.

US Patent:

20200123262, Apr 23, 2020

Filed:

May 24, 2019

Appl. No.:

16/422212

Inventors:

- Södertälje, SE
Christine Ward - Gaithersburg MD, US
Ubaldo Martin - Gaithersburg MD, US
Lorin Roskos - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US

International Classification:

C07K 16/28
A61P 11/00

Abstract:

Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

US Patent:

20180291108, Oct 11, 2018

Filed:

Nov 29, 2017

Appl. No.:

15/825526

Inventors:

- Sodertalje, SE
Christine Ward - Gaithersburg MD, US
Ubaldo Martin - Gaithersburg MD, US
Lorin Roskos - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US

International Classification:

C07K 16/28
A61K 39/00

Abstract:

Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

US Patent:

20170198049, Jul 13, 2017

Filed:

Sep 2, 2016

Appl. No.:

15/255508

Inventors:

- SÖDERTÄLJE, SE
Lorin Roskos - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US
Donald Raible - Berwyn PA, US

International Classification:

C07K 16/28

Abstract:

Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

US Patent:

20170107291, Apr 20, 2017

Filed:

May 31, 2016

Appl. No.:

15/168711

Inventors:

- Gaithersburg MD, US
Christine Ward - Gaithersburg MD, US
Ubaldo Martin - Gaithersburg MD, US
Lorin Roskos - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US

International Classification:

C07K 16/28

Abstract:

Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

US Patent:

20150158949, Jun 11, 2015

Filed:

Jun 12, 2013

Appl. No.:

14/407156

Inventors:

- Gaithersburg MD, US
Yihong Yao - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US
Lorin Roskos - Gaithersburg MD, US
Linda Chang - Gaithersburg MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

C07K 16/28
G06N 7/00
G06F 19/00
C12Q 1/68

Abstract:

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

US Patent:

20150104447, Apr 16, 2015

Filed:

Oct 14, 2014

Appl. No.:

14/513866

Inventors:

- Gaithersburg MD, US
Christine Ward - Gaithersburg MD, US
Ubaldo Martin - Gaithersburg MD, US
Lorin Roskos - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US

International Classification:

C07K 16/28

US Classification:

4241331

Abstract:

Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

US Patent:

20150044202, Feb 12, 2015

Filed:

Aug 7, 2014

Appl. No.:

14/453942

Inventors:

- Gaithersburg MD, US
Lorin Roskos - Gaithersburg MD, US
Bing Wang - Gaithersburg MD, US
Donald Raible - Berwyn PA, US

International Classification:

C07K 16/24

US Classification:

4241331

Abstract:

Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.